Major Milestone: FDA Greenlights Biannual HIV Prevention Injection
The U.S. Food and Drug Administration (FDA) has approved Gilead Sciences’ twice-a-year injectable medication for HIV prevention, a development the company has called a major leap forward in the battle against the virus. While pre-exposure prophylaxis (PrEP) has been available for over a decade, most options require daily oral dosing, limiting their overall impact on […]
Major Milestone: FDA Greenlights Biannual HIV Prevention Injection Read More »









